New biomarkers for diagnosis and prognosis of localized prostate cancer
Publication type: Journal Article
Publication date: 2018-10-01
scimago Q1
wos Q1
SJR: 4.016
CiteScore: 35.0
Impact factor: 15.7
ISSN: 1044579X, 10963650
PubMed ID:
29360504
Cancer Research
Abstract
The diagnostics and management of localized prostate cancer is complicated because of cancer heterogeneity and differentiated progression in various subgroups of patients. As a prostate cancer biomarker, FDA-approved detection assay for serum prostate specific antigen (PSA) and its derivatives are not potent enough to diagnose prostate cancer, especially high-grade disease (Gleason ≥7). To date, a collection of new biomarkers was developed. Some of these markers are superior for primary screening while others are particularly helpful for cancer risk stratification, detection of high-grade cancer, and prediction of adverse events. Two of those markers such as proPSA (a part of the Prostate Health Index (PHI)) and prostate specific antigen 3 (PCA3) (a part of the PCA3 Progensa test) were recently approved by FDA for clinical use. Other markers are not PDA-approved yet but are available from Clinical Laboratory Improvement Amendment (CLIA)-certified clinical laboratories. In this review, we characterize diagnostic performance of these markers and their diagnostic and prognostic utility for prostate cancer.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
|
|
|
Metabolites
2 publications, 4%
|
|
|
Cancers
2 publications, 4%
|
|
|
Prostate Cancer and Prostatic Diseases
2 publications, 4%
|
|
|
Prostate
2 publications, 4%
|
|
|
Carcinogenesis
2 publications, 4%
|
|
|
Aging
1 publication, 2%
|
|
|
Cancer Biomarkers
1 publication, 2%
|
|
|
European Journal of Histochemistry
1 publication, 2%
|
|
|
International Journal of Molecular Sciences
1 publication, 2%
|
|
|
Biomolecules
1 publication, 2%
|
|
|
Diagnostics
1 publication, 2%
|
|
|
Chemosensors
1 publication, 2%
|
|
|
Biosensors
1 publication, 2%
|
|
|
Frontiers in Oncology
1 publication, 2%
|
|
|
Indian Journal of Clinical Biochemistry
1 publication, 2%
|
|
|
Archives of Gynecology and Obstetrics
1 publication, 2%
|
|
|
Cancer Cell International
1 publication, 2%
|
|
|
Gene
1 publication, 2%
|
|
|
Functional and Integrative Genomics
1 publication, 2%
|
|
|
PLoS ONE
1 publication, 2%
|
|
|
Bioorganic Chemistry
1 publication, 2%
|
|
|
Clinical Genitourinary Cancer
1 publication, 2%
|
|
|
EBioMedicine
1 publication, 2%
|
|
|
Talanta
1 publication, 2%
|
|
|
Clinica Chimica Acta
1 publication, 2%
|
|
|
Journal of Pharmaceutical and Biomedical Analysis
1 publication, 2%
|
|
|
Cancer Reports
1 publication, 2%
|
|
|
Cell Biochemistry and Function
1 publication, 2%
|
|
|
Advanced Functional Materials
1 publication, 2%
|
|
|
1
2
|
Publishers
|
2
4
6
8
10
12
|
|
|
MDPI
11 publications, 22%
|
|
|
Elsevier
11 publications, 22%
|
|
|
Springer Nature
8 publications, 16%
|
|
|
Wiley
6 publications, 12%
|
|
|
Taylor & Francis
2 publications, 4%
|
|
|
Oxford University Press
2 publications, 4%
|
|
|
Impact Journals
1 publication, 2%
|
|
|
IOS Press
1 publication, 2%
|
|
|
PAGEPress Publications
1 publication, 2%
|
|
|
Frontiers Media S.A.
1 publication, 2%
|
|
|
Public Library of Science (PLoS)
1 publication, 2%
|
|
|
American Chemical Society (ACS)
1 publication, 2%
|
|
|
Royal Society of Chemistry (RSC)
1 publication, 2%
|
|
|
National Coordinating Centre for Health Technology Assessment
1 publication, 2%
|
|
|
AME Publishing Company
1 publication, 2%
|
|
|
2
4
6
8
10
12
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
50
Total citations:
50
Citations from 2024:
4
(8%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Chistiakov D. A. et al. New biomarkers for diagnosis and prognosis of localized prostate cancer // Seminars in Cancer Biology. 2018. Vol. 52. No. Pt 1. pp. 9-16.
GOST all authors (up to 50)
Copy
Chistiakov D. A., Myasoedova V., Grechko A. V., Melnichenko A. A., Orekhov A. N. New biomarkers for diagnosis and prognosis of localized prostate cancer // Seminars in Cancer Biology. 2018. Vol. 52. No. Pt 1. pp. 9-16.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1016/j.semcancer.2018.01.012
UR - https://doi.org/10.1016/j.semcancer.2018.01.012
TI - New biomarkers for diagnosis and prognosis of localized prostate cancer
T2 - Seminars in Cancer Biology
AU - Chistiakov, Dimitry A.
AU - Myasoedova, Veronika
AU - Grechko, Andrey V.
AU - Melnichenko, Alexandra A
AU - Orekhov, Alexander N.
PY - 2018
DA - 2018/10/01
PB - Elsevier
SP - 9-16
IS - Pt 1
VL - 52
PMID - 29360504
SN - 1044-579X
SN - 1096-3650
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2018_Chistiakov,
author = {Dimitry A. Chistiakov and Veronika Myasoedova and Andrey V. Grechko and Alexandra A Melnichenko and Alexander N. Orekhov},
title = {New biomarkers for diagnosis and prognosis of localized prostate cancer},
journal = {Seminars in Cancer Biology},
year = {2018},
volume = {52},
publisher = {Elsevier},
month = {oct},
url = {https://doi.org/10.1016/j.semcancer.2018.01.012},
number = {Pt 1},
pages = {9--16},
doi = {10.1016/j.semcancer.2018.01.012}
}
Cite this
MLA
Copy
Chistiakov, Dimitry A., et al. “New biomarkers for diagnosis and prognosis of localized prostate cancer.” Seminars in Cancer Biology, vol. 52, no. Pt 1, Oct. 2018, pp. 9-16. https://doi.org/10.1016/j.semcancer.2018.01.012.